The SURMOUNT-5 trial later confirmed that tirzepatide produced 47% greater weight loss than semaglutide in a head-to-head comparison, solidifying its position as a leading option for weight management
A phase Ib trial with a 4-week subcutaneous administration of either 10 mg or 15 mg tirzepatide once weekly in subjects with T2D led to a significant reduction in fasting plasma glucose concentrations (LSM difference [95% CI]: 49.12 mg/dl [78.14, 20.12] and 43.15 mg/dl [73.06, 13.21], respectively) and to reductions in body weight (LSM difference [95% CI]: 2.62 kg [3.79, 1.45] and 2.07 kg [3.25, 0.88], respectively
The $299 starter price is real but temporary for most patients
Set realistic goals: Sustainable weight loss is a gradual process, and rapid weight loss can be detrimental to overall health
This might include mild nausea, a sense of bloating, or slight changes in bowel habits